When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARQT - Arcutis initiates enrollment in mid-stage study of ARQ-252 in hand eczema
Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics (ARQT-2.8%) initiates enrollment in the Phase 2b portion of Phase 1/2b study of ARQ-252, selective topical small molecule Janus kinase type 1 inhibitor, in chronic hand eczema.
More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news,